AR100426A1 - ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 - Google Patents
ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3Info
- Publication number
- AR100426A1 AR100426A1 ARP150101480A ARP150101480A AR100426A1 AR 100426 A1 AR100426 A1 AR 100426A1 AR P150101480 A ARP150101480 A AR P150101480A AR P150101480 A ARP150101480 A AR P150101480A AR 100426 A1 AR100426 A1 AR 100426A1
- Authority
- AR
- Argentina
- Prior art keywords
- her3
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La solicitud se refiere a anticuerpos anti-HER3 (factor de crecimiento epidérmico 3) específicos que se unen a la horquilla b de HER3, a su preparación y su uso como medicamento. Reivindicación 2: Un anticuerpo aislado que se une a HER3 humana, en el que el anticuerpo comprende: a) un dominio variable de cadena pesada VH con la secuencia de aminoácidos de SEC ID Nº 33; y b) un dominio variable de cadena ligera VL con la secuencia de aminoácidos de SEC ID Nº 41, un dominio variable de cadena ligera con la secuencia de aminoácidos de SEC ID Nº 39 o un dominio variable de cadena ligera con la secuencia de aminoácidos de SEC ID Nº 42.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14168335 | 2014-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100426A1 true AR100426A1 (es) | 2016-10-05 |
Family
ID=50729374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101480A AR100426A1 (es) | 2014-05-14 | 2015-05-13 | ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9783611B2 (es) |
EP (1) | EP3143048B1 (es) |
JP (1) | JP6433511B2 (es) |
KR (1) | KR20160144465A (es) |
CN (1) | CN106459207B (es) |
AR (1) | AR100426A1 (es) |
BR (1) | BR112016024457A2 (es) |
CA (1) | CA2944895A1 (es) |
MX (1) | MX2016014416A (es) |
RU (1) | RU2016148682A (es) |
TW (1) | TW201605902A (es) |
WO (1) | WO2015173250A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6537970B2 (ja) | 2012-11-08 | 2019-07-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her3のベータヘアピン及びher4のベータヘアピンに結合する抗her3/her4抗原結合タンパク質 |
CN104755500B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹的HER3抗原结合蛋白 |
CA2944892A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 |
JP6433511B2 (ja) | 2014-05-14 | 2018-12-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her3のベータヘアピンに結合する抗her3抗体 |
CA3113207A1 (en) * | 2018-09-20 | 2020-03-26 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
EP0896586B2 (en) | 1996-03-27 | 2015-05-20 | Genentech, Inc. | ErbB3 ANTIBODIES |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US7244819B2 (en) | 2001-06-22 | 2007-07-17 | Roche Diagnostics Operations, Inc. | Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides |
AU2002326531A1 (en) | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
JP2009532393A (ja) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ErbB受容体由来ペプチド断片 |
AU2007257683A1 (en) | 2006-06-12 | 2007-12-21 | Symphogen A/S | Pan-cell surface receptor- specific therapeutics |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CA2759792A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
EP3546483A1 (en) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biological materials related to her3 |
EA036314B1 (ru) | 2010-08-20 | 2020-10-26 | Новартис Аг | Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
EA036739B1 (ru) | 2011-12-05 | 2020-12-15 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3) |
JP6537970B2 (ja) * | 2012-11-08 | 2019-07-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her3のベータヘアピン及びher4のベータヘアピンに結合する抗her3/her4抗原結合タンパク質 |
CN104755500B (zh) * | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹的HER3抗原结合蛋白 |
JP6433511B2 (ja) | 2014-05-14 | 2018-12-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her3のベータヘアピンに結合する抗her3抗体 |
-
2015
- 2015-05-12 JP JP2016567203A patent/JP6433511B2/ja not_active Expired - Fee Related
- 2015-05-12 MX MX2016014416A patent/MX2016014416A/es unknown
- 2015-05-12 CN CN201580022781.7A patent/CN106459207B/zh not_active Expired - Fee Related
- 2015-05-12 US US14/710,194 patent/US9783611B2/en active Active
- 2015-05-12 EP EP15721719.1A patent/EP3143048B1/en active Active
- 2015-05-12 KR KR1020167031609A patent/KR20160144465A/ko not_active Application Discontinuation
- 2015-05-12 CA CA2944895A patent/CA2944895A1/en not_active Abandoned
- 2015-05-12 WO PCT/EP2015/060492 patent/WO2015173250A1/en active Application Filing
- 2015-05-12 BR BR112016024457A patent/BR112016024457A2/pt not_active Application Discontinuation
- 2015-05-12 RU RU2016148682A patent/RU2016148682A/ru not_active Application Discontinuation
- 2015-05-13 TW TW104115311A patent/TW201605902A/zh unknown
- 2015-05-13 AR ARP150101480A patent/AR100426A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US9783611B2 (en) | 2017-10-10 |
CN106459207B (zh) | 2020-07-10 |
US20160002338A1 (en) | 2016-01-07 |
WO2015173250A1 (en) | 2015-11-19 |
EP3143048A1 (en) | 2017-03-22 |
JP6433511B2 (ja) | 2018-12-05 |
KR20160144465A (ko) | 2016-12-16 |
TW201605902A (zh) | 2016-02-16 |
MX2016014416A (es) | 2017-02-23 |
EP3143048B1 (en) | 2019-08-28 |
BR112016024457A2 (pt) | 2018-01-23 |
CA2944895A1 (en) | 2015-11-19 |
CN106459207A (zh) | 2017-02-22 |
RU2016148682A (ru) | 2018-06-19 |
JP2017521050A (ja) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
PE20130560A1 (es) | Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2 | |
CL2018001000A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr. | |
AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
CL2016001723A1 (es) | Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos. | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
PE20150002A1 (es) | Anticuerpos anti-fcrn | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
AR100426A1 (es) | ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 | |
RS54795B1 (sr) | Anti-her3 antitela i njihova korišćenja | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
BR112014019579A2 (pt) | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero | |
EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
BR112017013111A2 (pt) | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo | |
AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
EA201890082A1 (ru) | Эпитоп антитела | |
UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |